Mark E. Boulding
2018
In 2018, Mark E. Boulding earned a total compensation of $1.6M as Executive Vice President and Chief Legal Officer at PTC Therapeutics, a 43% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $312,567 |
|---|---|
| Option Awards | $847,686 |
| Salary | $434,120 |
| Other | $10,530 |
| Total | $1,604,903 |
Boulding received $847.7K in option awards, accounting for 53% of the total pay in 2018.
Boulding also received $312.6K in non-equity incentive plan, $434.1K in salary and $10.5K in other compensation.
Rankings
In 2018, Mark E. Boulding's compensation ranked 6,842nd out of 14,244 executives tracked by ExecPay. In other words, Boulding earned more than 52.0% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 6,842 out of 14,244 | 52nd |
Division Manufacturing | 2,620 out of 5,758 | 55th |
Major group Chemicals And Allied Products | 987 out of 2,119 | 53rd |
Industry group Drugs | 829 out of 1,808 | 54th |
Industry Pharmaceutical Preparations | 647 out of 1,382 | 53rd |
Source: SEC filing on April 25, 2019.
Boulding's colleagues
We found four more compensation records of executives who worked with Mark E. Boulding at PTC Therapeutics in 2018.